Relmada Therapeutics (RLMD) Tops Q1 EPS by 26c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.72), $0.26 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Streamflation drives 39% of Americans to cancel streaming in 6 months
• Faraday Future unveils nine robotics devices priced from $9,990